Business Context and Reporting Period
Company: Qualigen Therapeutics, Inc. (Note: Request metadata listed "Aixcrypto Holdings, Inc." but the filing text identifies Qualigen Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: July 28, 2025
Event: Entry into a Material Definitive Agreement for a private placement of Series A-3 Preferred Stock.
Key Financial Metrics
- Gross Proceeds: Approximately $4.5 million from the sale of 4,500 shares of Series A-3 Preferred Stock at $1,000 per share.
- Use of Proceeds: Working capital purposes; up to $500,000 may be used for investor relations agency fees.
- Conversion Terms: Initial conversion price of $2.80 per share (based on July 25, 2025 closing price), resulting in potential issuance of 1,607,143 shares of Common Stock.
- Financial Statements: The filing includes an unaudited pro forma balance sheet as of March 31, 2025, but does not provide specific revenue, profit, cash flow, or debt figures in the text.
Material Changes
- Capital Structure: Issuance of 4,500 shares of newly designated Series A-3 Preferred Stock (authorized: 10,000 shares).
- Anti-Dilution Adjustment: The issuance triggered an automatic adjustment to the conversion price of outstanding Series A-2 Preferred Stock, reducing it from $3.64 to $2.80 per share.
- Registration Rights: Agreement to file a Form S-1 registration statement within 45 days for the resale of Common Stock issuable upon conversion.
Outlook, Risks, and Unusual Items
- Anti-Dilution Protection: Series A-3 includes a "floor price" of $1.40 for conversion price adjustments in the event of future dilutive issuances.
- Beneficial Ownership Limitations: Holders cannot convert if it results in beneficial ownership exceeding 4.99% (expandable to 9.99% with 61 days' notice).
- Voting Rights: Series A-3 votes with Common Stock on an as-converted basis. Holders have veto rights (67% consent required) on charter amendments, repurchases of junior securities, and related-party transactions.
- Liquidation Preference: Senior to Common Stock but junior to Series A-2 Preferred Stock.
Investor Verification Checklist
- Verify the exact net proceeds after deducting placement agent fees and offering expenses.
- Review the unaudited pro forma balance sheet (Exhibit 99.2) for updated liquidity and debt positions.
- Confirm the total number of outstanding Series A-2 Preferred Stock shares to assess the full impact of the conversion price reduction.
- Monitor the filing of the Form S-1 registration statement within the required 45-day window.
- Check for any subsequent dilutive issuances that might trigger further conversion price adjustments down to the $1.40 floor.